Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion\'s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/06/18 | $5,000,000 | Series A |
Lagunita Biosciences | undisclosed |
